Preventive effect of celecoxib in sorafenib-related hand-foot syndrome in hepatocellular carcinoma patients, a single-center, open-label, randomized, controlled clinical phase III trial.
Jiancong Chen, Juncheng Wang, Yangxun Pan, Minjiang Yi, Jinbin Chen, Xiaohui Wang, Yizhen Fu, Yaojun Zhang, Li Xu, Minshan Chen, Rongxin Zhang, Zhongguo Zhou
Abstract
= 0.305). These results suggest that sorafenib + Celecoxib administration alleviated sorafenib-related skin toxicity. Longer PFS was achieved in clinical practice, although overall survival was not prolonged (ClinicalTrials.gov: NCT02961998).
Topics & Concepts
SorafenibMedicineHepatocellular carcinomaAdverse effectInternal medicineRashCelecoxibOncologyGastroenterologyClinical trialToxicityChemotherapy-related skin toxicityMultiple Myeloma Research and TreatmentsCancer Treatment and Pharmacology